NCT01297933Approved For Marketing不适用
Intravenous Omega-3 Fatty Acid (Omegaven) for Pediatric Patients With Total Parenteral Nutrition Associated Liver Dysfunction
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 1
研究概览
简要总结
A compassionate use protocol to provide Omegaven to pediatric patients with parenteral nutrition (PN) dependence and parenteral nutrition associated liver disease (PNALD).
详细描述
Omegaven is an intravenous fat emulsion (IFE) comprised of omega-3 fatty acids derived from fish oil. It will be used in an open label compassionate use treatment protocol, as an alternative to soybean oil (omega-6), as the sole IFE source of parenteral nutrition in an effort to reduce and/or reverse parenteral nutrition associated liver disease. The study will evaluate the safety and efficacy of Omegaven use in pediatric patients with PN dependence and PNALD.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PN dependence due to congenital or acquired gastrointestinal disease
- •Predicted PN requirement for at least an additional 30 days
- •Parenteral nutrition associated liver disease (PNALD), defined as two conjugated bilirubin levels >= 2 mg/dL at least one week apart, must be obtained to demonstrate persistence of PNALD
- •Failure to respond to standard therapies which may include cycling PN, reduction in the dose of soybean derived IFE, attempts to advance enteral feeds, ursodiol, metronidazole, and avoidance of excessive caloric provision
- •signed parent or legal guardian informed consent
排除标准
- •Acute treatable infection (e.g. urinary tract infection, sepsis)
- •Known allergy to egg or fish protein
- •Contraindications to Omegaven
- •Pregnancy
- •Serum triglyceride level greater than 400 mg/dL at baseline
- •History of severe hemolytic disorders or INR greater than 1.5 at baseline (INR cutoff of greater than 2 for infants less than 1 week of age)
研究者
Maria Mascarenhas
Section Chief, Clinical Nutrition
Children's Hospital of Philadelphia
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Omegaven as Alternative Parenteral Fat NutritionCholestasisCholestasis of Parenteral NutritionNCT03662282University of South Florida2
已完成
4 期
Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver DiseaseParenteral Nutrition Associated Liver DiseaseNCT00862446Vanderbilt University Medical Center48
No Longer Available
不适用
Omegaven Expanded Access ProtocolParenteral Nutrition Associated Liver DiseaseNCT02121769St. Luke's Health System, Boise, Idaho
Approved For Marketing
不适用
Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver DamageCholestasis of Parenteral NutritionNCT01861834Georgetown University
终止
2 期
Compassionate Use of Omegaven IV Fat EmulsionCholestasisTotal Parenteral Nutrition-induced CholestasisNCT00816348Cindy Haller15